U.S. Markets closed

Otonomy Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

  • OTIVIDEX™ Phase 3 trial in Ménière’s disease on track for results in first half 2020
  • OTO-313 Phase 1/2 trial in tinnitus expected to start in second quarter of 2019
  • OTO-413 Phase 1/2 trial in hearing loss expected to start in third quarter of 2019
  • $15 million term loan completed to extend cash runway into 2021

Conference call and webcast today at 4:30 p.m. EST

SAN DIEGO, March 04, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial results for the fourth quarter and year ended December 31, 2018 and provided an update on its product pipeline and corporate activities. The company will host a conference call and webcast today at 4:30 p.m. EST to discuss recent highlights and financial results.

"Our accomplishments in 2018 have positioned the company for significant advancement in 2019 as we continue enrollment of our Phase 3 trial of OTIVIDEX in Ménière’s disease, initiate Phase 1/2 clinical trials for OTO-313 in tinnitus and OTO-413 in hearing loss, and work towards delivering value-creating results for all three clinical trials in 2020," said David A. Weber, Ph.D., president and CEO of Otonomy. “We have also ensured that the necessary resources are in place to both complete these trials and continue to advance our exciting preclinical programs by carefully managing our expenses, establishing a co-promotion partnership for OTIPRIO®, and completing a debt financing that extends our cash runway into 2021. I look forward to sharing our plan and upcoming catalysts more broadly with investors during 2019."

Product Pipeline and Corporate Update

  • OTIVIDEX: Phase 3 trial in Ménière’s disease enrolling patients with results expected in the first half of 2020. Otonomy has completed one successful Phase 3 trial and is conducting this additional pivotal trial to support a submission for U.S. registration of OTIVIDEX in Ménière’s disease. The company plans to enroll approximately 160 patients, with the design and conduct of this trial based on the successful AVERTS-2 trial. Results from the AVERTS-2 trial were presented at the American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting in October 2018.

  • OTO-313: Phase 1/2 trial in tinnitus patients expected to start in the second quarter of 2019 with results in the first half of 2020. OTO-313 is a sustained-exposure formulation of the NMDA receptor antagonist gacyclidine. The Phase 1/2 clinical trial will include an initial safety cohort followed by an exploratory efficacy study that will enroll approximately 50 patients with unilateral tinnitus. An overview of the OTO-313 program was recently presented at the Association for Research in Otolaryngology (ARO) Annual Meeting.

  • OTO-413: Phase 1/2 trial in hearing loss patients expected to start in the third quarter of 2019 with results in the second half of 2020. OTO-413 is a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF) in development for the repair of cochlear synaptopathy, an underlying cause of hearing loss. The Phase 1/2 trial will enroll approximately 40 patients with speech-in-noise hearing loss. A presentation related to the OTO-413 program was recognized as a Neuroscience 2018 Hot Topic at the Society for Neuroscience (SfN) Annual Meeting in November 2018.

  • OTO-510: IND enabling activities to be initiated for cisplatin-induced hearing loss (CIHL) otoprotection program. CIHL is an important unmet medical need with no approved therapies and approximately 500,000 patients, including 5,000 children undergoing chemotherapy with ototoxic platinum-based agents each year in the United States. OTO-510 is a sustained-exposure formulation of an undisclosed small molecule designed for intratympanic administration to provide otoprotection without tumor protection.

  • OTO-6XX: Development candidate selected for regenerative hearing loss program. Otonomy has demonstrated regeneration of hair cells in a nonclinical proof-of-concept model using a class of small molecules formulated for sustained-exposure local delivery, and has selected a lead compound for development.

  • OTIPRIO: Co-promotion partnership with Mission Pharmacal in acute otitis externa (AOE) proceeding as planned. Preparations are underway for Mission to launch OTIPRIO to high volume pediatric and primary care physician offices in advance of the peak summer season for treating AOE.

  • $15 million Term Loan Completed to Extend Cash Runway into 2021. In December 2018, Otonomy completed a term loan financing with Oxford Finance LLC totaling $15 million. The loan provides for a 24-month interest-only repayment period, which can be extended upon successful results from the ongoing OTIVIDEX Phase 3 trial. There are no financial covenants or warrants associated with the loan.

Anticipated Upcoming Milestones

  • In second quarter of 2019, initiate a Phase 1/2 clinical trial of OTO-313 in tinnitus patients.

  • In third quarter of 2019, initiate a Phase 1/2 clinical trial of OTO-413 in hearing loss patients.

  • In first half of 2020, complete OTO-313 Phase 1/2 clinical trial.

  • In first half of 2020, complete Phase 3 trial for OTIVIDEX in Ménière’s disease.

  • In second half of 2020, complete OTO-413 Phase 1/2 clinical trial.

Fourth Quarter and Full Year 2018 Financial Highlights

  • Cash Position: Cash, cash equivalents, and short-term investments totaled $97.3 million as of December 31, 2018, compared to $120.0 million as of December 31, 2017. The cash balance for 2018 includes proceeds from a $15.0 million term loan provided by Oxford Finance LLC that was completed in December 2018.
     
  • Operating Expenses: GAAP operating expenses were $13.2 million for the fourth quarter of 2018, compared to $17.5 million for the fourth quarter of 2017. For the full year 2018, GAAP operating expenses were $51.9 million compared to $89.5 million for 2017. Non-GAAP operating expenses, which exclude stock-based compensation and rent abatement expense, were $10.8 million for the fourth quarter of 2018, compared to $14.3 million for the fourth quarter of 2017. For the full year 2018, non-GAAP operating expenses were $39.5 million compared to $73.8 million for 2017.
     
  • Research and Development Expenses: GAAP research and development (R&D) expenses for the fourth quarter of 2018 were $9.7 million, compared to $6.0 million for the fourth quarter of 2017. The increase was primarily due to increased costs for nonclinical and manufacturing activities to support initiation of clinical trials for OTO-313 and OTO-413. For the full year 2018, GAAP R&D expenses were $31.8 million compared to $42.7 million for 2017.
     
  • Selling, General and Administrative Expenses: GAAP selling, general and administrative (SG&A) expenses in the fourth quarter of 2018 were $3.6 million, compared to $11.5 million for the fourth quarter of 2017. The decrease was primarily a result of reduced selling expenses due to the discontinuation of promotional support for OTIPRIO. For the full year 2018, GAAP SG&A expenses were $20.0 million compared to $46.8 million for 2017.
     
  • Operating Expense Guidance:
    -- 2019: Otonomy expects that GAAP operating expenses will be in the range of $55-$60 million, and that non-GAAP operating expenses will be in the range of $45-$50 million.
    -- 2020: Otonomy expects that operating expenses will be lower than 2019 as multiple clinical trials are completed.
     
  • Cash Runway: Otonomy expects that its current cash, cash equivalents, and short term investments will be sufficient to fund the company through completion of the OTIVIDEX Phase 3 trial, OTO-313 Phase 1/2 trial, and OTO-413 Phase 1/2 trial in 2020, and will support company operations into 2021.

Webcast and Conference Call

Otonomy management will host a webcast and conference call regarding this announcement at 4:30 p.m. EST/1:30 p.m. PST today. The live call may be accessed by dialing (877) 305-6769 for domestic callers and (678) 562-4239 for international callers with conference ID code number: 9989017. A live webcast of the call will be available online in the investor relations section of Otonomy’s website at www.otonomy.com and will be archived there for 30 days.

Non-GAAP Operating Expenses

In this press release, Otonomy’s operating expenses are provided in accordance with generally accepted accounting principles (GAAP) in the United States and also on a non-GAAP basis. Non-GAAP operating expenses exclude stock-based compensation and rent abatement expense. Non-GAAP operating expenses are provided as a complement to operating expenses provided in accordance with GAAP because management believes non-GAAP operating expenses help indicate underlying trends in the company’s business, are important in comparing current results with prior period results and provide additional information regarding the company’s financial position. Management also uses non-GAAP operating expenses to establish budgets and operational goals that are communicated internally and externally and to manage the company’s business and to evaluate its performance. The attached financial information includes a reconciliation of the GAAP operating expenses to non-GAAP operating expenses and a reconciliation of GAAP operating expense guidance to non-GAAP operating expense guidance.

About Otonomy

Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière’s disease, hearing loss, and tinnitus. For additional information please visit www.otonomy.com.

Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or the future financial or operating performance of Otonomy. Forward-looking statements in this press release include, but are not limited to, timing of results, patient recruitment and enrollment plans for, and design and conduct of, the Phase 3 clinical trial for OTIVIDEX; timing of initiation and results, patient recruitment and enrollment plans for, and design and conduct of,  the Phase 1/2 clinical trial for OTO-313; timing of initiation and results, patient recruitment and enrollment plans for, and design and conduct of, the Phase 1/2 clinical trial for OTO-413; expectations regarding IND enabling activities for OTO-510; expectations regarding OTO-6XX development; the activity and timing of launch under, and potential benefits of, the co-promotion agreement between Otonomy and Mission; the benefits of the loan provided by Oxford Finance LLC and the potential extension of the interest-only period; expectations regarding the timing and nature of upcoming milestones; expectations regarding operating expenses for 2019 and 2020; expectations that current capital is sufficient to fund the company through completion of the OTIVIDEX Phase 3 trial, OTO-313 Phase 1/2 trial, and OTO 413 Phase 1/2 trial, and will support company operations into 2021; and statements by Otonomy’s president and CEO. Otonomy’s expectations regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties. Actual results may differ materially from those indicated by these forward-looking statements as a result of these risks and uncertainties, including but not limited to: Otonomy’s limited operating history and its expectation that it will incur significant losses for the foreseeable future; Otonomy’s ability to accurately forecast financial results; Otonomy’s ability to obtain additional financing; Otonomy’s dependence on the regulatory success and advancement of its product candidates; the uncertainties inherent in the clinical drug development process, including, without limitation, Otonomy’s ability to adequately demonstrate the safety and efficacy of its product candidates, the nonclinical and clinical results for its product candidates, which may not support further development, and challenges related to patient enrollment in clinical trials; Otonomy’s ability to obtain regulatory approval for its product candidates; the risks of the occurrence of any event, change or other circumstance that could give rise to the termination of the co-promotion agreement between Otonomy and Mission; the risks of the occurrence of any event, change or other circumstance that could impact Otonomy’s ability to repay or comply with the terms of the loan provided by Oxford Finance LLC; side effects or adverse events associated with Otonomy’s product candidates; Otonomy’s ability to successfully commercialize its product candidates, if approved; competition in the biopharmaceutical industry; Otonomy’s dependence on third parties to conduct nonclinical studies and clinical trials; Otonomy’s dependence on third parties for the manufacture of its product candidates; Otonomy’s dependence on a small number of suppliers for raw materials; Otonomy’s ability to protect its intellectual property related to its product candidates in the United States and throughout the world; expectations regarding potential market size, opportunity and growth; Otonomy’s ability to manage operating expenses; implementation of Otonomy’s business model and strategic plans for its business, products and technology; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled "Risk Factors" in Otonomy’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 4, 2019, and Otonomy’s future reports to be filed with the SEC. The forward-looking statements in this press release are based on information available to Otonomy as of the date hereof. Otonomy disclaims any obligation to update any forward-looking statements, except as required by law.

Contacts:

Media Inquiries
Spectrum Science
Leticia Diaz
Vice President
202.587.2517
ldiaz@spectrumscience.com

Investor Inquiries
Westwicke Partners
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com

  Otonomy, Inc.
  Condensed Balance Sheet Data
  (in thousands)
         
    As of December 31,   As of December 31,
      2018       2017  
         
  Cash and cash equivalents $ 33,633     $ 18,456  
         
  Short-term investments   63,651       101,548  
         
  Total assets   104,992       128,364  
         
  Long-term debt, net   14,764       -  
         
  Total liabilities   25,255       11,085  
         
  Accumulated deficit   (415,218 )     (364,850 )
         
  Total stockholders' equity   79,737       117,279  


Otonomy, Inc.
Condensed Statements of Operations
(in thousands, except share and per share data)
                 
    Three Months Ended   Years Ended
    December 31,   December 31,
      2018       2017       2018       2017  
                 
    (unaudited)        
Product sales, net $ 208     $ 270     $ 745     $ 1,236  
Costs and operating expenses:              
  Cost of product sales   271       1,948       946       3,098  
  Research and development   9,669       6,041       31,844       42,701  
  Selling, general and administrative   3,580       11,451       20,008       46,838  
Total costs and operating expenses   13,520       19,440       52,798       92,637  
Loss from operations   (13,312 )     (19,170 )     (52,053 )     (91,401 )
                 
Other income, net   467       337       1,685       1,271  
Net loss $ (12,845 )   $ (18,833 )   $ (50,368 )   $ (90,130 )
                 
Net loss per share, basic and diluted $ (0.42 )   $ (0.62 )   $ (1.65 )   $ (2.97 )
                 
Weighted-average shares used to compute net loss per share,              
  basic and diluted   30,646,951       30,375,053       30,610,244       30,304,158  
                 


Otonomy, Inc.
Reconciliation of GAAP to Non-GAAP Operating Expenses
(in thousands)
                 
    Three Months Ended   Years Ended
    December 31,   December 31,
      2018       2017       2018       2017  
                                 
GAAP operating expenses              
  Research and development $ 9,669     $ 6,041     $ 31,844     $ 42,701  
  Selling, general and administrative   3,580       11,451       20,008       46,838  
Total GAAP operating expenses   13,249       17,492       51,852       89,539  
Non-GAAP adjustments              
  R&D stock-based compensation expense   (1,075 )     (597 )     (4,447 )     (3,763 )
  SG&A stock-based compensation expense   (1,375 )     (2,592 )     (7,955 )     (9,878 )
  Rent abatement   -       -       -       (2,084 )
Total non-GAAP adjustments   (2,450 )     (3,189 )     (12,402 )     (15,725 )
Non-GAAP operating expenses $ 10,799     $ 14,303     $ 39,450     $ 73,814  
                 


Otonomy, Inc.
Reconciliation of 2019 GAAP to Non-GAAP Operating Expense Guidance
(in millions)
     
     
GAAP operating expenses $55 - $60
Non-GAAP adjustments  
  Stock-based compensation expense $10
Non-GAAP operating expenses $45 - $50
     

  • Here are Warren Buffett's top 15 stock holdings
    Business
    Yahoo Finance

    Here are Warren Buffett's top 15 stock holdings

    Some of the top holdings include American Express (AXP), Apple (AAPL), Bank of America (BAC), and Delta Airlines DAL , according to Buffett's widely-read annual letter. Buffett wrote that he doesn't view these investments as "stock market wagers — dalliances to be terminated because of downgrades by 'the Street,' an earnings' miss,' expected Federal Reserve actions, possible political developments, forecasts by economists or whatever else might be the subject du jour." Rather than stock holdings, Buffett views these as companies Berkshire Hathaway "partly owns."

  • Business
    Barrons.com

    If Coronavirus Is Killing Fewer People Than the Flu, Why Has Beijing Quarantined Millions?

    China's Leaders on the Hot Seat Market Intelligence Report by TIS Group Feb. 21: Over the past several days, we have detailed some, though not all, of the actions being taken by China's government to control the coronavirus outbreak. I was told today that roughly 50,000 people die in China each year from the flu. If the coronavirus is just another flu-like virus and the current death toll really is about 2,000, not 50,000, why then has Beijing locked down 750 million people?

  • Morgan Stanley is paying $2,500 per customer for E-Trade. You can earn a $3,500 sign-up bonus for signing with a new broker — with one major catch
    Business
    MarketWatch

    Morgan Stanley is paying $2,500 per customer for E-Trade. You can earn a $3,500 sign-up bonus for signing with a new broker — with one major catch

    If the latest Wall Street mega-deal doesn't make you want to switch online brokerage accounts for a lucrative sign-up bonus, maybe it should. Wall Street giant Morgan Stanley announced an agreement Thursday to pay $13 billion to acquire the online brokerage E-Trade which has 5.2 million customer accounts. “The combination will significantly increase the scale and breadth of Morgan Stanley's Wealth Management franchise, and positions Morgan Stanley to be an industry leader in Wealth Management across all channels and wealth segments,” Morgan Stanley said in a statement.

  • Opinion: Bernie Sanders and the Missing $25 Trillion
    U.S.
    WSJ

    Opinion: Bernie Sanders and the Missing $25 Trillion

    During the Democratic debate on Feb. 19, 2020, Pete Buttigieg skewered Bernie Sanders over the high cost of his plans. Image: Mike Blake/Reuters

  • How Does My Spousal Social Security Benefit Work?
    Politics
    Investopedia

    How Does My Spousal Social Security Benefit Work?

    If you have never worked or paid Social Security taxes (or not paid them for long enough), you will not be eligible to receive Social Security retirement benefits on your own account. You will also be able to apply for Medicare at age 65 as long as your spouse is at least 62. If you apply before you have reached full retirement age and your own benefit is larger, you will automatically be paid that amount.

  • ‘Overprotected’ investors could get stung in the next recession, warns top Barclays strategist
    Business
    MarketWatch

    ‘Overprotected’ investors could get stung in the next recession, warns top Barclays strategist

    Rattled by rising non-China coronavirus cases — notably in South Korea — investors appear unwilling to load up on stocks heading into the weekend. Welcome to the world of helicopter investing and our call of the day from Barclays Wealth Management's chief investment officer William Hobbs, who finds overly anxious investors living in the “long shadow” caused by the financial crisis. “The most common narrative in markets is what to do when the next recession comes along — own Treasurys, own gold, own quality to such an extent that my concern would almost be that if the next recession is of a more normal variety, such as a stock retracement of 10% to 15% and moderate declines in unemployment, you'll find that you have overprotected yourself and the underperformance could actually be in the areas which you thought were giving you safety,” Hobbs told MarketWatch.

  • Business
    TheStreet.com

    Berkshire Hathaway Posts Profit of $29.2B With Near-Record Cash

    Warren Buffett's Berkshire Hathaway on Saturday swung to a profit in the fourth quarter vs. a year-earlier Kraft Heinz -induced loss as well as cash on hand that remains at near-record levels as the conglomerate's collective investments continued to churn out positive returns. The Omaha, Nebraska-based company on Saturday said it earned net income in the quarter of $29.2 billion, or $17,909 per Class A share equivalent, up from a loss of $25.4 billion, or $15,467 a share, the year before. The year-ago results were dragged down largely by an unexpected write-down at Kraft Heinz, of which Berkshire is a significant shareholder.

  • Warren Buffett says Berkshire is '100% prepared' for his death, details what will happen to his stock
    Business
    Yahoo Finance

    Warren Buffett says Berkshire is '100% prepared' for his death, details what will happen to his stock

    Investing icon Warren Buffett says Berkshire Hathaway (BRK-A, BRK-B) is "100% prepared" for his death, and detailed what will happen to his shares in that event. In his widely-read annual letter, Buffett told the story of how his friend received "an irritating letter" from a local newspaper seeking biographical data for an obituary. Buffett, whose net worth is estimated by Forbes to be $90.2 billion, has 99% of his net worth in Berkshire shares.

  • Warren Buffett reveals a big change to this year's annual shareholder meeting
    Business
    Yahoo Finance

    Warren Buffett reveals a big change to this year's annual shareholder meeting

    Warren Buffett just announced a major tweak to the format of Berkshire Hathaway's (BRK-A, BRK-B) famed Annual Meeting, informing shareholders that vice chairs Ajit Jain and Greg Abel will take part in the question and answer session. Every year, nearly 40,000 shareholders from across the globe descend on Omaha, Nebraska to listen to Buffett, 89, and his right-hand man Charlie Munger, 96, answer questions and deliver investing wisdom, life advice, and the occasional quip.

  • How Much Are Taxes on an IRA Withdrawal?
    Business
    Investopedia

    How Much Are Taxes on an IRA Withdrawal?

    How much you will pay in taxes on an individual retirement account (IRA) withdrawal depends on the type of IRA, your age, and the purpose of the withdrawal. In other cases, you owe income tax on the money you withdraw and sometimes an additional penalty if you withdraw funds before age 59½. There are a number of IRA options and a variety of places to open these accounts, but the Roth IRA and the traditional IRA are by far the most widely held types.

  • Business
    Bloomberg

    Buffett Spends Record $2.2 Billion Buying Berkshire Shares

    Buffett's Berkshire Hathaway Inc., which loosened its repurchase policy almost two years ago after being stymied on the dealmaking front, has since taken a cautious approach to buybacks, acquiring only $6.3 billion of stock. In the fourth quarter, Buffett bought shares every month, and has no plans to slow down, if the price is right. “Shareholders having at least $20 million in value of A or B shares and an inclination to sell shares to Berkshire may wish to have their broker contact Berkshire's Mark Millard,” Buffett said in his annual letter to shareholders Saturday.

  • Mason Hawkins' Southeastern Buys 4 Stocks in 4th Quarter
    Business
    GuruFocus.com

    Mason Hawkins' Southeastern Buys 4 Stocks in 4th Quarter

    Southeastern Asset Management recently disclosed its portfolio updates for the third quarter of 2019. Founded by Mason Hawkins (Trades, Portfolio) in 1975, the Memphis, Tennessee-based firm manages the Longleaf Partners Funds. GuruFocus has detected 4 Warning Sign with WMB.

  • Warren Buffett is 'almost certain' that stocks will beat bonds over time if rates stay low
    Business
    Yahoo Finance

    Warren Buffett is 'almost certain' that stocks will beat bonds over time if rates stay low

    While Warren Buffett doesn't prognosticate on where interest rates are heading, the legendary 89-year-old investor expects stocks to continue to outperform bonds over time. Our perhaps jaundiced view is that the pundits who opine on these subjects reveal, by that very behavior, far more about themselves than they reveal about the future. What we can say is that if something close to current rates should prevail over the coming decades and if corporate tax rates also remain near the low level businesses now enjoy, it is almost certain that equities will over time perform far better than long-term, fixed-rate debt instruments,” Buffett wrote in Berkshire Hathaway's (BRK-A, BRK-B) widely-read a...

  • Why Warren Buffett wants you to ignore Berkshire's $53.7 billion gain on stocks
    Business
    Yahoo Finance

    Why Warren Buffett wants you to ignore Berkshire's $53.7 billion gain on stocks

    Warren Buffett cautions investors against putting too much emphasis on Berkshire Hathaway's (BRK-A, BRK-B) $81.4 billion in net earnings for 2019. During the period, the company run by Buffett reported $53.7 billion in unrealized gains on its equity investments. That $53.7 billion gain requires comment,” Buffett said.

  • Business
    Barrons.com

    Stocks Drop on the Week but Still Look Bubbly. Time to Prepare for a Correction.

    The last time we got to these levels, the bubble burst and a 50%-plus global bear market began,” Consider the trading action in the market's most popular stocks. The FAANGs— (FB) (ticker: FB), (AAPL) (AAPL), (AMZN) (AMZN), (NFLX) (NFLX), and Google parent (GOOGL) (GOOGL)—are up 10% year to date, adding more than $330 billion in market value to the S&P 500. What's more, the average price/earnings ratio for FAANG stocks has jumped to 35 times estimated earnings from 21 times last year.

  • Dividend ETFs To Buy And Watch For 2020
    Business
    Investor's Business Daily

    Dividend ETFs To Buy And Watch For 2020

    Dividends have long been a favorite of investment gurus from Warren Buffett to late Vanguard Group founder John Bogle, and it's easy to see why. Individual stocks can provide income, but dividend ETFs are an easy way to gain exposure to a basket of dividend-paying stocks. With a stock dividend, a company distributes additional shares instead of cash.

  • 3 Marijuana Stocks Poised to Lead a Sector Rebound
    Business
    TipRanks

    3 Marijuana Stocks Poised to Lead a Sector Rebound

    As the Canadian cannabis market continues to fail to meet sales projections, the licensed producers (LPs) with the best balance sheets are poised to lead a market rebound. With both Aurora Cannabis and Tilray implementing restructurings, the industry could see a void in certain markets providing opportunities for companies with the ability to fund growth initiatives. Based on the Aurora restructuring, the company is exiting several international markets along with shifting a focus to a value brand.

  • Justice Department announces $3 billion settlement with Wells Fargo
    Business
    ABC News Videos

    Justice Department announces $3 billion settlement with Wells Fargo

    Over 15 years, Wells Fargo employees made 2 million fake accounts, and the government said $500 million of the settlement will go to investors.

  • Kraft Heinz Stock Is Not Worth Chasing
    Business
    InvestorPlace

    Kraft Heinz Stock Is Not Worth Chasing

    Berkshire Hathaway (NYSE:BRK.A,NYSE:BRK.B), led by famed investor Warren Buffett, remains a major shareholder, and in fact helped lead the merger between Kraft and Heinz. It doesn't take that much of a close look to see what's wrong with Kraft Heinz and with Kraft Heinz stock.

  • Michael Bloomberg says it’s not so ‘simple’ to produce his tax returns — here’s what most high-income tax returns have in common
    Politics
    MarketWatch

    Michael Bloomberg says it’s not so ‘simple’ to produce his tax returns — here’s what most high-income tax returns have in common

    Michael Bloomberg, the billionaire former New York City mayor running for the Democratic presidential nod, says he will release his tax returns — but that's no easy feat. “I can't go to TurboTax,” Bloomberg, the founder and CEO of the global media and financial data company Bloomberg L.P., told Democratic debate moderators on Wednesday night. Bloomberg, who is worth $65.2 billion according to Forbes, said he makes money from all over the globe, so his tax payments are complex.

  • Stanley Druckenmiller's Top 6 Buys in the 4th Quarter
    Business
    GuruFocus.com

    Stanley Druckenmiller's Top 6 Buys in the 4th Quarter

    Stanley Druckenmiller (Trades, Portfolio), the CEO of Duquesne Family Office, disclosed last week that his top six buys for the fourth quarter of 2019 were in iShares Russell 2000 (IWM), iShares MSCI Emerging Index Fund (EEM), JPMorgan Chase & Co. (NYSE:JPM), Alphabet Inc. NASDAQ:GOOGL), Freeport-McMoRan Inc. NYSE:FCX) and FedEx Corp.

  • Biotech Stock Crumbles Despite Esperion Nabbing A Key Drug Approval
    Business
    Investor's Business Daily

    Biotech Stock Crumbles Despite Esperion Nabbing A Key Drug Approval

    Shares of Esperion Therapeutics crumbled Friday after the biotech company's cholesterol medicine gained Food and Drug Administration approval — with some caveats. The cholesterol medicine formerly known as bempedoic acid will sell as Nexletol, a once-daily oral treatment for high LDL cholesterol. The drug is specifically approved for patients with a genetic form of high cholesterol or a type of cardiovascular disease.

  • Here’s three reasons why the 30-year Treasury yield plunged to a record low
    Business
    MarketWatch

    Here’s three reasons why the 30-year Treasury yield plunged to a record low

    The U.S. 30-year Treasury bond yield dropped to an all-time low on Friday, sparking worries among investors who wonder what it's saying about the economy's future prospects. Analysts say the slump in the long bond's yield this week reflects a confluence of factors including easy Federal Reserve monetary policy, concerns about the COVID-19 epidemic's impact on economic growth, and an absence of inflationary pressures. Historically, a slump in long-term yields can indicate fears that growth will start to disappoint and inflation will fall which may make the real return on bonds more attractive.

  • Bernie Sanders possibly running against President Trump is starting to scare investors: strategist
    Politics
    Yahoo Finance

    Bernie Sanders possibly running against President Trump is starting to scare investors: strategist

    There is a growing undercurrent in markets that say a battle this fall between self-described socialist Senator Bernie Sanders and President Donald Trump could be bad news for stock prices. As evidenced by the market's strong run-up in 2020, investors have yet to exit stocks on fears of a big government Bernie winning the Oval Office. But his continued strong showing in debates and national polls may lead to some profit-taking sooner rather than later.

  • This Is What a Comfortable Retirement Will Cost in Your State
    Business
    GOBankingRates

    This Is What a Comfortable Retirement Will Cost in Your State

    To be more precise, you'd need to save $2,017,597.95 to comfortably cover living expenses for 20 years in retirement. It takes over $100,000 per year to comfortably live in Washington thanks to high housing costs of $44,704 and the highest cost of groceries in the nation. California A comfortable retirement costs: $85,893.44 a year Costs in the Golden State are exceedingly high, primarily due to housing costs at about double the national average and the second-highest transportation costs in the country.